Loading clinical trials...
Loading clinical trials...
An Open-label, First-in-human, Dose Escalation Study of SAR440234 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), or High Risk Myelodysplasia (HR-MDS)
Conditions
Interventions
SAR440234
Locations
4
United States
Investigational Site Number 8400001
Houston, Texas, United States
Investigational Site Number 2500004
Marseille, France
Investigational Site Number 2500001
Paris, France
Investigational Site Number 2500003
Villejuif, France
Start Date
October 24, 2018
Primary Completion Date
February 6, 2021
Completion Date
February 6, 2021
Last Updated
May 24, 2022
NCT07203742
NCT07148180
NCT05534620
NCT07117136
NCT06355583
NCT06345365
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions